 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Celldex Therapeutics
CLDX
Conference or Release date: November 10, 2025 press release only
Celldex Jumps on CDX-0159 Data [June 15, 2020 @ Seeking Alpha]
Celldex Breast Cancer Phase 2 Study of glembatumumab vedotin fails [April 16, 2018]
Celldex Value Depends on Coming Data [February 8, 2018 @ Seeking Alpha]
Celldex Set to Bounce Back [April 15, 2015 @ Seeking Alpha]
Celldex Therapeutics (CLDX) is a biotechnology company developing therapies for cancers.
but did until 9/16/2020
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALLO |
| ALNY |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BMY |
| CLDX |
| CLSN |
| FATE |
| GILD |
| GLYC |
| ILMN |
| INO |
| IONS |
| INCY |
| MCHP |
| MRNA |
| PLX |
| REGN |
| RNA |
| SANA |
| SAGE |
| VRTX |
| VSTM |
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is investment journalism, not financial advice.
Copyright 2025 William P. Meyers